Cargando…

The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A

Diabetes mellitus (DM) is an independent risk factor for overactive bladder (OAB). The pathophysiology of DM-associated OAB is multifactorial and time-dependent. Diabetic bladder dysfunction is highly associated with diabetic complications, mainly including diabetic neuropathy and atherosclerosis. C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chung-Cheng, Jiang, Yung-Hong, Kuo, Hann-Chorng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150832/ https://www.ncbi.nlm.nih.gov/pubmed/32188046 http://dx.doi.org/10.3390/toxins12030186

Ejemplares similares

Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome
por: Liao, Chun-Hou, et al.
Publicado: (2015)

Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis
por: Chen, Jing-Liang, et al.
Publicado: (2020)

Efficacy of Intravesical Botulinum Toxin A Injection in the Treatment of Refractory Overactive Bladder in Children
por: Fan, Yu-Hua, et al.
Publicado: (2023)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
por: Chen, Sheng-Fu, et al.
Publicado: (2020)

Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders
por: Hung, Fan-Ching, et al.
Publicado: (2022)

Individualizing medical treatment of overactive bladder
por: Kuo, Hann-Chorng
Publicado: (2018)

Botulinum toxin A for the Treatment of Overactive Bladder
por: Hsieh, Po-Fan, et al.
Publicado: (2016)

Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome
por: Liu, Hsin-Tzu, et al.
Publicado: (2015)

Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders—From Bench to Bedside
por: Jiang, Yuan-Hong, et al.
Publicado: (2020)

Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder—Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes
por: Ou, Yin-Chien, et al.
Publicado: (2023)

Effect of Botulinum Toxin A on Bladder Pain—Molecular Evidence and Animal Studies
por: Yeh, Ting-Chun, et al.
Publicado: (2020)

The use of botulinum toxin for the treatment of overactive bladder syndrome
por: Orasanu, Bogdan, et al.
Publicado: (2013)

Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders
por: Jhang, Jia-Fong, et al.
Publicado: (2021)

Botulinum Toxin Brings a Light to the Shadow of Functional Urology
por: Kuo, Hann-Chorng
Publicado: (2023)

Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action
por: Jhang, Jia-Fong, et al.
Publicado: (2016)

Intravesical Injection of Botulinum Toxin Type A in Men without Bladder Outlet Obstruction and Post-Deobstructive Prostate Surgery
por: Lee, Hsiang-Ying, et al.
Publicado: (2023)

Emerging treatments for overactive bladder: clinical potential of botulinum toxins
por: Tincello, Douglas G, et al.
Publicado: (2014)

Botulinum toxin-A for the treatment of overactive bladder: UK contributions
por: Seth, JH, et al.
Publicado: (2013)

Botulinum Toxin Paves the Way for the Treatment of Functional Lower Urinary Tract Dysfunction
por: Kuo, Hann-Chorng
Publicado: (2020)

Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
por: Kuo, Yuh-Chen, et al.
Publicado: (2016)

Learning Curve of Botulinum Toxin Bladder Injection for the Treatment of Refractory Overactive Bladder
por: Barba, Marta, et al.
Publicado: (2022)

Recurrent urinary tract infection in women and overactive bladder – Is there a relationship?
por: Ke, Qian-Sheng, et al.
Publicado: (2020)

Therapeutic Effects of Botulinum Toxin A, via Urethral Sphincter Injection on Voiding Dysfunction Due to Different Bladder and Urethral Sphincter Dysfunctions
por: Lee, Yu-Khun, et al.
Publicado: (2019)

The Overactive Bladder Symptom Score, International Prostate Symptom Score–Storage Subscore, and Urgency Severity Score in Patients With Overactive Bladder and Hypersensitive Bladder: Which Scoring System is Best?
por: Chuang, Fei-Chi, et al.
Publicado: (2018)

Treatment Outcomes of Intravesical Botulinum Toxin A Injections on Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Yu, Wan-Ru, et al.
Publicado: (2022)

Practical points in the medical treatment of overactive bladder and nocturia in the elderly
por: Chen, Jing-Liang, et al.
Publicado: (2016)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
por: Kuo, Yuh-Chen, et al.
Publicado: (2021)

Botulinum Toxin in Neurogenic Detrusor Overactivity
por: D'Ancona, Carlos Arturo Levi, et al.
Publicado: (2012)

Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose?
por: Lee, Cheng-Ling, et al.
Publicado: (2023)

Mirabegron in Overactive Bladder and Its Role in Exit Strategy After Botulinum Toxin Treatment in Children
por: Tan, Denise Jia Yun, et al.
Publicado: (2022)

Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder
por: Chen, Sheng-Fu, et al.
Publicado: (2016)

Botulinum Toxin A Injection for Autonomic Dysreflexia—Detrusor Injection or Urethral Sphincter Injection?
por: Chow, Po-Ming, et al.
Publicado: (2023)

How to choose appropriate medication for overactive bladder: Findings from the largest integrated clinical trial database analysis of mirabegron studies
por: Kuo, Hann-Chorng
Publicado: (2020)

Deterioration of bladder compliance after botulinum toxin A injection and discontinuation of medication for overactive bladder
por: Wada, Naoki, et al.
Publicado: (2022)

Increased Serum Adipokines Implicate Chronic Inflammation in the Pathogenesis of Overactive Bladder Syndrome Refractory to Antimuscarinic Therapy
por: Liu, Hsin-Tzu, et al.
Publicado: (2013)

Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction
por: Jiang, Yuan-Hong, et al.
Publicado: (2020)

Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome
por: Hsiao, Sheng-Mou, et al.
Publicado: (2016)

Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice
por: Wang, Hsiu-Jen, et al.
Publicado: (2021)

Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Wang, Hsiu-Jen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4369ih445losd4v6seatc88pgb